Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of TheraCIM-hR3 (YMB1000) in Patients With Solid Tumours

NCT00369252 is registered in ClinicalTrials.gov with YM BioSciences as lead sponsor.

NCT NCT00369252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00369252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of TheraCIM-hR3 (YMB1000) in Patients With Solid Tumours
Lead sponsor
YM BioSciences
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2005
Completion date
Not reported
Enrollment
18
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced and/or metastatic solid tumours